Page 74 - Demo

Chapter 372References1. Elsea SH, Williams SR. Smith-Magenis syndrome: Haploinsufficiency of RAI1 results in altered gene regulation in neurological and metabolic pathways. Expert Rev Mol Med. 2011. 2. Boot E, Linders CC, Tromp SH, van den Boogaard MJ, van Eeghen AM. Possible underreporting of pathogenic variants in RAI1 causing Smith–Magenis syndrome. American Journal of Medical Genetics, Part A. 2021. 3. Edelman EA, Girirajan S, Finucane B, Patel PI, Lupski JR, Smith ACM, et al. Gender, genotype, and phenotype differences in Smith-Magenis syndrome: A meta-analysis of 105 cases. Clin Genet. 2007;71(6). 4. Elsea SH, Girirajan SS. Smith-Magenis syndrome. Eur J Hum Genet. 2008.5. Laje G, Morse R, Richter W, Ball J, Pao M, Smith ACM. Autism spectrum features in SmithMagenis syndrome. Am J Med Genet Part C Semin Med Genet. 2010. 6. Poisson A, Nicolas A, Cochat P, Sanlaville D, Rigard C, De Leersnyder H, et al. Behavioral disturbance and treatment strategies in Smith-Magenis syndrome. Orphanet J Rare Dis. 2015. 7. Greenberg F, Guzzetta V, De Oca-Luna RM, Magenis RE, Smith ACM, Richter SF, et al. Molecular analysis of the Smith-Magenis syndrome: A possible contiguous- gene syndrome associated with del(17)(p11.2). Am J Hum Genet. 1991. 8. Sloneem J, Oliver C, Udwin O, Woodcock KA. Prevalence, phenomenology, aetiology and predictors of challenging behaviour in Smith-Magenis syndrome. J Intellect Disabil Res. 2011. 9. Shayota BJ, Elsea SH. Behavior and sleep disturbance in Smith-Magenis syndrome. Current Opinion in Psychiatry. 2019. 10. Shelley BP, Robertson MM. The neuropsychiatry and multisystem features of the SmithMagenis Syndrome: A review. Journal of Neuropsychiatry and Clinical Neurosciences. 2005. 11. Fidler DJ, Hodapp RM, Dykens EM. Stress in families of young children with down syndrome, williams syndrome, and smith-magenis syndrome. Early Educ Dev. 2000. 12. Hodapp RM, Fidler DJ, Smith ACM. Stress and coping in families of children with SmithMagenis syndrome. J Intellect Disabil Res. 1998. 13. Nag HE, Hoxmark LB, Nærland T. Parental experiences with behavioural problems in Smith–Magenis syndrome: The need for syndrome-specific competence. J Intellect Disabil. 2019. 14. Laje G, Bernert R, Morse R, Pao M, Smith ACM. Pharmacological treatment of disruptive behavior in Smith-Magenis syndrome. Am J Med Genet Part C Semin Med Genet. 2010.15. Faraone S V., Spencer T, Aleardi M, Pagano C, Biederman J. Meta-Analysis of the Efficacy of Methylphenidate for Treating Adult Attention-Deficit/Hyperactivity Disorder. Journal of Clinical Psychopharmacology. 2004. 16. Hanwella R, Senanayake M, de Silva V. Comparative efficacy and acceptability of methylphenidate and atomoxetine in treatment of attention deficit hyperactivity disorder in children and adolescents: A meta-analysis. BMC Psychiatry. 2011.17. Schachter HM, Pham B, King J, Langford S, Moher D. How efficacious and safe is short-acting methylphenidate for the treatment of attention-deficit disorder in children and adolescents? A meta-analysis. CMAJ. 2001.18. Cheon KA, Ryu YH, Kim JW, Cho DY. The homozygosity for 10-repeat allele at dopamine transporter gene and dopamine transporter density in Korean children with attention deficit hyperactivity disorder: Relating to treatment response to methylphenidate. Eur Neuropsychopharmacol. 2005.19. van der Poest Clement E, Jansen FE, Braun KPJ, Peters JM. Update on Drug Management of Refractory Epilepsy in Tuberous Sclerosis Complex. Pediatric Drugs. 2020. 20. De Kuijper G, Evenhuis H, Minderaa RB, Hoekstra PJ. Effects of controlled discontinuation of long-term used antipsychotics for behavioural symptoms in individuals with intellectual disability. J Intellect Disabil Res. 2014.21. Bradbury J, Avila C, Grace S. Practice-Based Research in Complementary Medicine: Could N-of-1 Trials Become the New Gold Standard? Healthcare. 2020.Annelieke Muller sHL.indd 72 14-11-2023 09:07